scholarly journals Fatigue in Pediatric Oncology Patients

10.5772/33068 ◽  
2012 ◽  
Author(s):  
Hatice Bal
Keyword(s):  
Pediatric Oncology ◽  
Oncology Patients

Psychosocial Functioning of Fathers of Pediatric Oncology Patients

2006 ◽  
Author(s):  
Kristina K. Hardy ◽  
Melanie J. Bonner ◽  
Katherine C. Hutchinson ◽  
Victoria W. Willard
Keyword(s):  
Pediatric Oncology ◽  
Psychosocial Functioning ◽  
Oncology Patients

Perceived Impact of Illness During Treatment in Pediatric Oncology Patients

2007 ◽  
Author(s):  
Stephen R. Lassen ◽  
Brent Collett ◽  
Stan Whitsett ◽  
Debra Friedman
Keyword(s):  
Pediatric Oncology ◽  
Oncology Patients ◽  
Perceived Impact

New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients

2007 ◽  
Vol 83 (7) ◽  
pp. 54-63 ◽  
Author(s):  
Ana Verena Almeida Mendes ◽  
Roberto Sapolnik ◽  
Núbia Mendonça
Keyword(s):  
Febrile Neutropenia ◽  
Pediatric Oncology ◽  
Clinical Management ◽  
Oncology Patients ◽  
New Guidelines

Risk factors associated with the development of oral mucositis in pediatric oncology patients: Systematic review and meta‐analysis

Oral Diseases ◽  
2021 ◽  
Author(s):  
Amanda de Farias Gabriel ◽  
Felipe Martins Silveira ◽  
Marina Curra ◽  
Lauren Frenzel Schuch ◽  
Vivian Petersen Wagner ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Oral Mucositis ◽  
Pediatric Oncology ◽  
Meta Analysis ◽  
Oncology Patients ◽  
Factors Associated

Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for Pneumocystis jirovecii pneumonia in pediatric oncology patients

2020 ◽  
pp. 107815522097904
Author(s):  
Monica Awad ◽  
Caroline M Sierra ◽  
Elhaam Mesghali ◽  
Khaled Bahjri
Keyword(s):  
Pediatric Oncology ◽  
Retrospective Cohort ◽  
Hematologic Malignancies ◽  
Primary Objective ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Weekly Dose ◽  
Single Center ◽  
Oncology Patients ◽  
Prophylaxis Therapy

Current recommendations for prophylaxis of Pneumocystis jirovecii pneumonia in oncology patients include administration of trimethoprim/sulfamethoxazole (TMP/SMX) three times weekly or the same total weekly dose given daily. The primary objective of this study was to evaluate the efficacy of two consecutive days per week of TMP/SMX for prevention of Pneumocystis jirovecii pneumonia (PJP) in pediatric oncology patients. A retrospective cohort, single-center analysis was conducted in oncology patients 21 years and younger who received TMP/SMX for PJP prophylaxis between February 1, 2013 and July 31, 2017. Changes to the prophylaxis regimen were documented and analyzed. A total of 322 patients received TMP/SMX on two consecutive days per week for PJP prevention, of whom four had confirmed PJP (1.3%). Neutropenia was the most common reason for switching to alternative prophylaxis therapy (11.5%). Two consecutive prophylaxis days with TMP/SMX may be insufficient to prevent PJP in children with hematologic malignancies. Neutropenia remains a barrier for TMP/SMX use for PJP prophylaxis. Further studies to compare PJP incidence in children receiving alternative prophylaxis regimens should be considered.

Diagnosis of Invasive Fungal Infection Among Pediatric Oncology Patients

2019 ◽  
Vol 41 (8) ◽  
pp. 596-600 ◽  
Author(s):  
Erica I. Hodgman ◽  
Jeffrey Compton ◽  
Faisal G. Qureshi ◽  
Joseph T. Murphy
Keyword(s):  
Fungal Infection ◽  
Pediatric Oncology ◽  
Invasive Fungal Infection ◽  
Oncology Patients
Sign in / Sign up

Export Citation Format

Share Document